Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of risankizumab versus placebo in active psoriatic arthritis with inadequate response or intolerance to at least one DMARD
MOH_2018-12-25_004756Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriatic arthritis (PsA) and plaque psoriasis comparing Placebo then open-label risankizumab with Risankizumab then open-label risankizumab (2 arms). Started Nov 2018; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on MOH_2018-12-25_004756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-12-25_004756.